SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

NCT04948788 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: SHR1459 ；YY-20394
DRUG: SHR1459 ；YY-20394
DRUG: Gemcitabine-Oxaliplatin

Sponsor

Jiangsu HengRui Medicine Co., Ltd.